Exposure to Antibiotics Before Immune Checkpoint Inhibitor Therapy and Overall Survival in Elderly Patients with Cancer
Exposure to antibiotics during the first year after starting immune checkpoint inhibitor therapy has been found to be associated with worse survival among patients with cancer aged 65 years or older.
After conducting multiple studies, it was found that 59% of patients that received antibiotics during the first year and 19% during the 60 days after starting immune checkpoint inhibitors, researchers have observed that exposure to antibiotics, specifically fluoroquinolones, before immune checkpoint inhibitor therapy was associated with worse overall survival among older adults with cancer. Interventions targeted at altering the gut microbiome to increase immunogenicity may help improve outcomes for patients receiving immune checkpoint inhibitors with prior antibiotic exposure.
Lawson Eng, MD, SM, from the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, is the corresponding author of the article in the Journal of Clinical Oncology.
Disclosure: The study was supported by ICES, which is funded by an annual grant from the Ministry of Health and Long-Term Care of Ontario, the ASCO/Conquer Cancer Foundation Young Investigator Award, and others. For full disclosure information on the study authors, visit ascopubs.org.
Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment and
Overall Survival in Older Patients With Cancer – The ASCO Post. (s. f.). https://ascopost.com/news/march-2023/antibiotic-exposure-before-immune-checkpoint-inhibitor-treatment-and-overall-survival-in-older-patients-with-cancer/?utm_source=TAP-EN-030823-Trending_LUNG